The Exchange has sought clarification from Pfizer Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.
PFIZER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE has asked Pfizer Limited to clarify discrepancies found in the financial results submitted in XBRL format for the quarter ended September 30, 2025, under Regulation 33 of SEBI's Listing Obligations and Disclosure Requirements. The query relates to technical filing format issues rather than the substance of the numbers. The company has not yet responded to the exchange. Such clarifications are common and typically resolved with a corrective filing or explanation.
This appears to be a routine technical compliance query and is unlikely to materially affect the stock. Investors should wait for the company's response to understand if the discrepancies point to anything substantive beyond formatting errors.